Commercial Vehicle Group, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Commercial Vehicle Group, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $188.34M | Mar 12, 2018 |
| FY2017 | Sep 30, 2017 | $198.35M | Mar 12, 2018 |
| FY2017 | Jun 30, 2017 | $195.13M | Mar 12, 2018 |
| FY2017 | Mar 31, 2017 | $173.42M | Mar 12, 2018 |
| FY2017 | Dec 31, 2016 | $149.97M | Mar 12, 2018 |
| FY2017 | Sep 30, 2016 | $153.60M | Mar 12, 2018 |
| FY2017 | Jun 30, 2016 | $178.25M | Mar 12, 2018 |
| FY2017 | Mar 31, 2016 | $180.29M | Mar 12, 2018 |
| FY2016 | Dec 31, 2015 | $184.69M | Mar 9, 2017 |
| FY2016 | Sep 30, 2015 | $202.73M | Mar 9, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $649.00M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $723.36M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $835.47M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $782.58M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $971.58M | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | $216.00M | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | $187.70M | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | $126.90M | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | $187.11M | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | $189.49M | Mar 9, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.39M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $73.12M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $121.09M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $85.03M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $118.99M | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | $23.14M | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | $24.16M | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | $6.48M | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | $20.30M | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | $10.17M | Mar 9, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.78M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($27.87M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $49.41M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | ($21.97M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $23.73M | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | ($4.14M) | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | $4.18M | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | ($12.50M) | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | ($24.59M) | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | ($7.53M) | Mar 9, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($656.0K) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($758.0K) | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $39.87M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $24.82M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $49.58M | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | $4.98M | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | $8.89M | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | ($10.52M) | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | ($26.52M) | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | ($4.28M) | Mar 9, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $7.00M | Mar 9, 2017 |
| FY2016 | Dec 31, 2015 | $7.40M | Mar 9, 2017 |
| FY2016 | Dec 31, 2014 | $6.30M | Mar 9, 2017 |
| FY2015 | Dec 31, 2013 | $6.00M | Mar 11, 2016 |
| FY2014 | Dec 31, 2012 | $6.40M | Mar 16, 2015 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.04M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $73.88M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $81.22M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $60.21M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $69.41M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $68.23M | Mar 6, 2023 |
| FY2019 | Dec 31, 2019 | $13.57M | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $17.53M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $16.25M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $15.20M | Mar 16, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.64M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($33.45M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $38.28M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $68.95M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($29.83M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $34.37M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $36.75M | Mar 2, 2022 |
| FY2019 | Sep 30, 2019 | $28.51M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $8.75M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($5.97M) | Mar 16, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.65M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $18.52M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $19.70M | Mar 10, 2026 |
| FY2024 | Dec 31, 2022 | $19.71M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $17.65M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $7.14M | Mar 6, 2023 |
| FY2021 | Dec 31, 2019 | $24.00M | Mar 2, 2022 |
| FY2019 | Sep 30, 2019 | $18.74M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $12.80M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $5.58M | Mar 16, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $391.71M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $424.57M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $483.21M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $470.27M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $507.69M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $454.37M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $435.83M | Mar 9, 2021 |
| FY2019 | Sep 30, 2019 | $462.49M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $452.71M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $447.01M | Mar 16, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $258.36M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $288.98M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $310.28M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $350.23M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $381.04M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $359.00M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $307.14M | Mar 9, 2021 |
| FY2019 | Sep 30, 2019 | $331.71M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $323.82M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $326.94M | Mar 16, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $133.36M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $135.59M | Mar 10, 2026 |
| FY2025 | Dec 31, 2023 | $172.93M | Mar 10, 2026 |
| FY2025 | Dec 31, 2022 | $120.04M | Mar 10, 2026 |
| FY2024 | Dec 31, 2021 | $126.65M | Mar 17, 2025 |
| FY2023 | Dec 31, 2020 | $95.37M | Mar 14, 2024 |
| FY2022 | Dec 31, 2019 | $128.69M | Mar 6, 2023 |
| FY2019 | Sep 30, 2019 | $130.79M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $128.89M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $120.07M | Mar 16, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | $27.82M | Mar 9, 2021 |
| FY2019 | Sep 30, 2019 | $25.19M | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $7.62M | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $7.59M | Mar 16, 2020 |
| FY2020 | Dec 31, 2018 | $7.58M | Mar 9, 2021 |
| FY2019 | Sep 30, 2018 | $7.37M | Mar 16, 2020 |
| FY2019 | Jun 30, 2018 | $7.66M | Mar 16, 2020 |
| FY2019 | Mar 31, 2018 | $7.94M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $8.05M | Mar 11, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($96.83M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($74.05M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | ($46.18M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($95.60M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($73.62M) | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | ($97.36M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | ($60.31M) | Mar 9, 2021 |
| FY2019 | Sep 30, 2019 | ($52.77M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | ($59.95M) | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($66.10M) | Mar 16, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $72.70M | Mar 17, 2014 |
| FY2013 | Dec 31, 2012 | $68.37M | Mar 17, 2014 |
| FY2013 | Dec 31, 2011 | $87.96M | Mar 17, 2014 |
| FY2013 | Dec 31, 2010 | $42.59M | Mar 17, 2014 |
| FY2012 | Dec 31, 2009 | $9.52M | Mar 11, 2013 |
| FY2011 | Dec 31, 2008 | $7.31M | Mar 13, 2012 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.95M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $135.50M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | $141.51M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $152.44M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $194.96M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | $146.58M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $156.38M | Mar 9, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 1 | Mar 14, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 14, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 9, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Mar 9, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Mar 9, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 1 | Mar 14, 2024 |
| FY2023 | Dec 31, 2022 | 0 | Mar 14, 2024 |
| FY2023 | Dec 31, 2021 | 0 | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Mar 9, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Mar 9, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Mar 9, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Mar 9, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 9, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Mar 9, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Mar 9, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 34.19M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 33.69M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 33.32M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 32.83M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 32.03M | Mar 6, 2023 |
| FY2021 | Dec 31, 2020 | 31.25M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | 30.80M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | 30.51M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 30.22M | Mar 11, 2019 |
| FY2017 | Dec 31, 2016 | 29.87M | Mar 12, 2018 |